Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria.
Biochim Biophys Acta Mol Basis Dis. 2020 Feb 1;1866(2):165349. doi: 10.1016/j.bbadis.2018.11.024. Epub 2018 Dec 13.
Although massive efforts have been undertaken to elucidate the etiology of the pregnancy syndrome preeclampsia, its developmental origin remains a mystery. Most efforts of the last decade have focused on biomarkers to predict and/or diagnose preeclampsia, including the anti-angiogenic factor sFlt-1 (soluble fms-like tyrosin kinase-1), the angiogenic factor PGF (placental growth factor) and PP13 (placental protein 13). The origins of these marker proteins are still under debate, and so far their actions have only been describe separate from each other. This study will focus on the origins and actions of all three markers during pregnancy and outside pregnancy and will describe a scenario where all three markers act synergistically to rescue the mother from the deleterious effects of the debris that is released from the placenta during preeclampsia. This more holistic approach may open new avenues to think about maternal-fetal interactions and putative therapies.
尽管人们已经付出了巨大努力来阐明妊娠综合征子痫前期的病因,但它的发育起源仍然是一个谜。过去十年的大多数研究都集中在预测和/或诊断子痫前期的生物标志物上,包括抗血管生成因子 sFlt-1(可溶性 fms 样酪氨酸激酶-1)、血管生成因子 PGF(胎盘生长因子)和 PP13(胎盘蛋白 13)。这些标记蛋白的起源仍存在争议,到目前为止,它们的作用仅被描述为彼此独立。本研究将重点关注这三种标志物在妊娠期间和妊娠期间的起源和作用,并描述一种情况,即所有三种标志物协同作用,从子痫前期胎盘释放的碎片对母亲造成的有害影响中拯救母亲。这种更全面的方法可能为思考母婴相互作用和潜在治疗方法开辟新途径。